Correlation Between Gain Therapeutics and Inhibikase Therapeutics

Can any of the company-specific risk be diversified away by investing in both Gain Therapeutics and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Gain Therapeutics and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Gain Therapeutics and Inhibikase Therapeutics, you can compare the effects of market volatilities on Gain Therapeutics and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Gain Therapeutics with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Gain Therapeutics and Inhibikase Therapeutics.

Diversification Opportunities for Gain Therapeutics and Inhibikase Therapeutics

0.62

Correlation Coefficient

Gain Therapeutics  Inhibikase Therapeutics

Poor diversification

The 3 months correlation between Gain and Inhibikase is 0.62. Overlapping area represents the amount of risk that can be diversified away by holding Gain Therapeutics and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and Gain Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Gain Therapeutics are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of Gain Therapeutics i.e., Gain Therapeutics and Inhibikase Therapeutics go up and down completely randomly.

Pair Corralation between Gain Therapeutics and Inhibikase Therapeutics

Given the investment horizon of 90 days Gain Therapeutics is expected to generate 1.27 times less return on investment than Inhibikase Therapeutics. In addition to that, Gain Therapeutics is 1.06 times more volatile than Inhibikase Therapeutics. It trades about 0.15 of its total potential returns per unit of risk. Inhibikase Therapeutics is currently generating about 0.2 per unit of volatility. If you would invest  134.00  in Inhibikase Therapeutics on August 31, 2024 and sell it today you would earn a total of  139.00  from holding Inhibikase Therapeutics or generate 103.73% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Gain Therapeutics  vs.  Inhibikase Therapeutics

Gain Therapeutics

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Gain Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Gain Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Inhibikase Therapeutics

Risk-Adjusted Performance

15 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Inhibikase Therapeutics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady forward-looking signals, Inhibikase Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Gain Therapeutics and Inhibikase Therapeutics

The main advantage of trading using opposite Gain Therapeutics and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Gain Therapeutics position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.

The idea behind Gain Therapeutics and Inhibikase Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.